ORBIMED ADVISORS LLC 13D and 13G filings for ORIC Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-12-27 4:36 pm Sale | 2022-12-22 | 13D | ORIC Pharmaceuticals, Inc. ORIC | ORBIMED ADVISORS LLC | 1,787,569 4.500% | -425,002 (-19.21%) | Filing |
| 2021-08-12 4:17 pm Sale | 2021-08-10 | 13D | ORIC Pharmaceuticals, Inc. ORIC | ORBIMED ADVISORS LLC | 2,212,571 5.600% | -254,721 (-10.32%) | Filing |
| 2021-03-19 6:06 pm Sale | 2021-03-17 | 13D | ORIC Pharmaceuticals, Inc. ORIC | ORBIMED ADVISORS LLC | 2,467,292 6.800% | -298,425 (-10.79%) | Filing |
| 2020-11-18 2:42 pm Unchanged | 2020-11-17 | 13D | ORIC Pharmaceuticals, Inc. ORIC | ORBIMED ADVISORS LLC | 2,765,717 7.800% | 0 (Unchanged) | Filing |
| 2020-05-01 4:15 pm Purchase | 2020-04-28 | 13D | ORIC Pharmaceuticals, Inc. ORIC | ORBIMED ADVISORS LLC | 2,765,717 9.200% | 2,765,717 (New Position) | Filing |